Efficacy News and Research

RSS
Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic second-quarter net loss increases to $1.1 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Pharmasset receives fast track designation from FDA for PSI-7977

Pharmasset receives fast track designation from FDA for PSI-7977

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Study demonstrates efficacy of vertebroplasty in treatment of acute vertebral compression fractures

Study demonstrates efficacy of vertebroplasty in treatment of acute vertebral compression fractures

NPL CaviMeter fine-tunes equipment to produce right quantity and distribution of cleaning action

NPL CaviMeter fine-tunes equipment to produce right quantity and distribution of cleaning action

Somaxon second-quarter net loss reduces to $5.7 million

Somaxon second-quarter net loss reduces to $5.7 million

ASMBS, SRC announce new 5-year agreement for Bariatric Surgery Center of Excellence program

ASMBS, SRC announce new 5-year agreement for Bariatric Surgery Center of Excellence program

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

Advanced Life Sciences second-quarter net loss decreases to $2.1 million

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Agile initiates Phase 3 NEW CHOICE Study of AG200-15 contraceptive patch

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.